Amgen (LTS:0R0T) Cyclically Adjusted Book per Share: $23.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R0T Amgen Inc LTS:0R0T
90 GF Score
Price $362.41
GF Value $354.37
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted Book per Share?

Amgen LTS:0R0T -1.97% 90 Cyclically Adjusted Book per Share is $23.87 as of Mar. 2026. GuruFocus rates LTS:0R0T with a GF Score™ of 90/100 and a GF Value™ of $354.37 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Amgen's adjusted book value per share for the three months ended in Mar. 2026 was $17.028. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $23.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted Book Growth Rate was -10.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Amgen was 38.80% per year. The lowest was -7.60% per year. And the median was 12.60% per year.

As of today (2026-07-19), Amgen's current stock price is $362.41. Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $23.87. Amgen's Cyclically Adjusted PB Ratio of today is 15.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amgen was 16.00. The lowest was 4.86. And the median was 7.48.


Amgen  (LTS:0R0T) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=362.41/23.87
=15.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amgen was 16.00. The lowest was 4.86. And the median was 7.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Amgen Cyclically Adjusted Book per Share Related Terms


Amgen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted Book per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.74 30.71 29.36 26.93 24.38

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.65 25.86 24.83 24.38 23.87

LTS:0R0T vs GILD, PFE, BMY: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PB Ratio falls into.


LTS:0R0T
90GF Score
Amgen Inc LTS:0R0T
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.028/330.2130*330.2130
=17.028

Current CPI (Mar. 2026) = 330.2130.

Amgen Quarterly Data

Book Value per Share CPI Adj_Book
201606 40.236 241.018 55.126
201609 41.317 241.428 56.511
201612 40.481 241.432 55.367
201703 41.621 243.801 56.373
201706 43.413 244.955 58.523
201709 44.356 246.819 59.343
201712 34.950 246.524 46.815
201803 23.439 249.554 31.015
201806 22.972 251.989 30.103
201809 22.403 252.439 29.305
201812 19.854 251.233 26.095
201903 17.630 254.202 22.902
201906 17.927 256.143 23.111
201909 18.328 256.759 23.571
201912 16.356 256.974 21.018
202003 16.131 258.115 20.637
202006 18.177 257.797 23.283
202009 18.781 260.280 23.827
202012 16.270 260.474 20.626
202103 16.225 264.877 20.227
202106 14.479 271.696 17.597
202109 14.543 274.310 17.507
202112 12.001 278.802 14.214
202203 1.715 287.504 1.970
202206 4.522 296.311 5.039
202209 6.847 296.808 7.618
202212 6.856 296.797 7.628
202303 10.009 301.836 10.950
202306 12.677 305.109 13.720
202309 14.308 307.789 15.350
202312 11.640 306.746 12.530
202403 9.371 312.332 9.907
202406 11.034 314.175 11.597
202409 14.004 315.301 14.666
202412 10.944 315.605 11.451
202503 11.545 319.799 11.921
202506 13.799 322.561 14.126
202509 17.863 324.800 18.161
202512 16.069 324.054 16.374
202603 17.028 330.213 17.028

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $23.87 mean?
Amgen (LTS:0R0T) has a Cyclically Adjusted Book per Share of $23.87 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted Book per Share too high?
Amgen's current Cyclically Adjusted Book per Share is $23.87. Overall, Amgen has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted Book per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted Book per Share of $23.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted Book per Share is $23.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (LTS:0R0T) is currently considered Fairly Valued. The stock's GF Value™ is $354.37, compared to a current price of $362.41 — trading 2.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is $23.87. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Amgen (LTS:0R0T), the current Cyclically Adjusted Book per Share is $23.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (LTS:0R0T) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of $362.41 is trading 2.3% above its estimated GF Value™ of $354.37. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for LTS:0R0T:

  • Cyclically Adjusted Book per Share: $23.87
  • GF Value™: $354.37 vs. price of $362.41 (2.3% above fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the LTS:0R0T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score

Get the complete analysis for LTS:0R0T

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$362.41
Price
$354.37
GF Value